The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH)
on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem …

In the era of targeted therapies, haematopoietic stem-cell transplantation (HSCT), both
allogeneic and autologous, remains a curative approach for patients with chemosensitive …

Background Findings of retrospective studies suggest that sorafenib maintenance post-
transplantation might reduce relapse in patients with FLT3 internal tandem duplication (FLT3 …

Background Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal
prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax …

Haploidentical stem cell transplantation (haplo-SCT) achieves superior or at least
comparable clinical outcomes to HLA-matched sibling donor transplantation (MSDT) in …

Acute myeloid leukemia (AML) is a heterogeneous clonal disease associated with a dismal
survival, partly due to the frequent occurrence of relapse. Many patient-and leukemia …

Background The use of post-transplant cyclophosphamide (PTCy) is highly effective in
preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting …

Background The heterogeneity of relapsed or refractory (R/R) acute myeloid leukemia (AML)
leads to no response to venetoclax (VEN)–based therapy in more than half of the patients …

A multistage model instructed by a large dataset (knowledge bank [KB] algorithm) has
recently been developed to improve outcome predictions and tailor therapeutic decisions …

Background Compared with HLA-matched sibling donor (MSD) transplant, the outcomes of
haploidentical donor (HID) transplant for refractory acute leukemia need to be further …